Pharmacokinetic and pharmacodynamic evaluation of nitrofurantoin against Escherichia coli in a murine urinary tract infection model.
Escherichia coli
Nitrofurantoin
mouse infection model
pharmacokinetic/pharmacodynamic
urinary tract infection
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
01
02
2024
accepted:
18
03
2024
medline:
1
4
2024
pubmed:
1
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
The antimicrobial agent nitrofurantoin is becoming increasingly important for treatment of urinary tract infections (UTIs) due to widespread occurrence of multidrug-resistant Escherichia coli. Despite many years of use, little data on nitrofurantoin pharmacokinetics (PK) or -dynamics (PD) exist. The objective of this study was to (i) evaluate the pharmacokinetics of nitrofurantoin in a mouse model and (ii) use that data to design an in vivo dose fractionation study in an experimental model of UTI with E. coli for determination of the most predictive PK/PD index. Nitrofurantoin concentrations in urine were approximately 100-fold larger than concentrations in plasma after oral administration of 5, 10, and 20 mg/kg nitrofurantoin. The area under the curve over the minimum inhibitory concentration (AUC/MIC) was weakly correlated to bacterial reduction in urine (r
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology.
Références
De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33(3):e00181‐19.
Ny S, Edquist P, Dumpis U, Grondahl‐Yli‐Hannuksela K, Hermese J, Kling AM, et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25–34.
Kahlmeter G, Ahman J, Matuschek E. Antimicrobial resistance of Escherichia coli causing uncomplicated urinary tract infections: a European update for 2014 and comparison with 2000 and 2008. Infect Dis Ther. 2015;4(4):417–423.
Sanchez GV, Babiker A, Master RN, Luu T, Mathur A, Bordon J. Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016;60(5):2680–2683.
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):E103–E120.
Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta‐analysis of controlled trials. J Antimicrob Chemother. 2015;70(9):2456–2464.
Porreca A, D'Agostino D, Romagnoli D, Del Giudice F, Maggi M, Palmer K, et al. The clinical efficacy of nitrofurantoin for treating uncomplicated urinary tract infection in adults: a systematic review of randomized control trials. Urol Int. 2021;105(7–8):531–540.
Wijma RA, Fransen F, Muller AE, Mouton JW. Optimizing dosing of nitrofurantoin from a PK/PD point of view: what do we need to know? Drug Resist Updat. 2019;43:1–9.
Lindgren PK, Klockars O, Malmberg C, Cars O. Pharmacodynamic studies of nitrofurantoin against common uropathogens. J Antimicrob Chemother. 2015;70(4):1076–1082.
Fransen F, Melchers MJB, Meletiadis J, Mouton JW. Pharmacodynamics and differential activity of nitrofurantoin against ESBL‐positive pathogens involved in urinary tract infections. J Antimicrob Chemother. 2016;71(10):2883–2889.
Fransen F, Melchers MJB, Lagarde CMC, Meletiadis J, Mouton JW. Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections. J Antimicrob Chemother. 2017;72(12):3366–3373.
Jakobsen L, Hammerum AM, Frimodt‐Møller N. Virulence of Escherichia coli B2 isolates from meat and animals in a murine model of ascending urinary tract infectionn (UTI): evidence that UTI is a zoonosis. J Clin Microbiol. 2010;48(8):2978–2980.
CLSI. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard. 4th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
Jakobsen L, Cattoir V, Jensen KS, Hammerum AM, Nordmann P, Frimodt‐Møller N. Impact of low‐level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model. J Antimicrob Chemother. 2012;67(10):2438–2444.
Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol. 2005;67(5):1758–1764.
Hvidberg H, Struve C, Krogfelt KA, Christensen N, Rasmussen SN, Frimodt‐Møller N. Development of a long‐term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob Agents Chemother. 2000;44(1):156–163.
Kerrn MB, Frimodt‐Møller N, Espersen F. Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse model. Antimicrob Agents Chemother. 2003;47(3):1002–1009.
Frimodt‐Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents. 2002;19(6):546–553.
Domańska U, Pobudkowska A, Pelczarska A, Zukowski L. Modelling, solubility and pK(a) of five sparingly soluble drugs. Int J Pharm. 2011;403(1–2):115–122.
Jakobsen L, Lundberg CV, Frimodt‐Møller N. Ciprofloxacin pharmacokinetics/pharmacodynamics against susceptible and low‐level resistant Escherichia coli isolates in an experimental ascending urinary tract infection model in mice. Antimicrob Agents Chemother. 2020;65(1): e01804‐20.